Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. Journal of vascular and interventional radiology : JVIR Buettner, S., Braat, A. J., Margonis, G. A., Brown, D. B., Taylor, K. B., Borgmann, A. J., Kappadath, S. C., Mahvash, A., IJzermans, J. N., Weiss, M. J., Lamarca, A., Bell, J. K., Valle, J. W., Hagendoorn, J., Koerkamp, B. G., Sze, D. Y., Lam, M. G. 2020

Abstract

To report outcomes of yttrium-90 (90Y) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma (ICC).Retrospective review was performed of 115 patients at 6 tertiary care centers; 92 were treated with resin microspheres (80%), 22 were treated with glass microspheres (19%), and 1 was treated with both. Postintervention outcomes were compared between groups with ?2 tests. Survival after diagnosis and after treatment was assessed by Kaplan-Meier method.Grade 3 laboratory toxicity was observed in 4 patients (4%); no difference in toxicity profile between resin and glass microspheres was observed (P = .350). Clinical toxicity per Society of Interventional Radiology criteria was noted in 29 patients (25%). Partial response per Response Evaluation Criteria In Solid Tumors 1.1 was noted in 25% of patients who underwent embolization with glass microspheres and 3% of patients who were treated with resin microspheres (P = .008). Median overall survival (OS) from first diagnosis was 29 months (95% confidence interval [CI], 21-37 mo) for all patients, and 1-, 3-, and 5-year OS rates were 85%, 31%, and 8%, respectively. Median OS after treatment was 11 months (95% CI, 8-13 mo), and 1- and 3-year OS rates were 44% and 4%, respectively. These estimates were not significantly different between resin and glass microspheres (P = .730 and P = .475, respectively). Five patients were able to undergo curative-intent resection after 90Y radioembolization (4%).This study provides observational data of treatment outcomes after 90Y radioembolization in patients with unresectable ICC.

View details for DOI 10.1016/j.jvir.2020.02.008

View details for PubMedID 32473757